A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Inclusion Criteria: Part 1:

1. Adults aged 45 years or older with a diagnosis of nAMD
2. Diagnosis in the study eye of active, pathologic, newly diagnosed and treatment naïve (i.e., no previous anti-VEGF treatment or other surgery in the study eye)
3. Visual acuity from 20/25 to 20/200 in the study eye
4. Total lesion size (including neovascularization, blood) ≦12 disc areas (30.5 mm2) asassessed by Fluorescein Angiography.
5. Demonstrate the ability, or have a family member who is willing and able to, instilltopical ocular drops in the study eye.
6. Ability to give written informed consent and comply with study procedures. Part 2:
7. Adults aged 45 years or older with a diagnosis of nAMD.
8. Participant with nAMD previously treated with 3 injections of Aflibercept within thepreceding 4 months, and received the last injection within 30 to 21 days before visit 1 of this study.
9. Demonstrate the ability, or have a family member who is willing and able to, instiltopical ocular drops in the study eye.
10. Ability to give written informed consent and comply with study procedures.

Exclusion Criteria: Part 1:

1. Prior use within the last 2 months, or a high possibility of requiring treatment withanti-VEGF therapy (except the study drug) in both eyes during the study.
2. Abnormal regions identified by Fundus Autofluorescence (FAF) and Optical CoherenceTomography (OCT) involving the center of the fovea are caused by retinal pigmentepithelium (RPE) atrophy, RPE tear, photoreceptor attenuation, or fibrosis/scartissue.
3. Significant retinal serous pigment epithelial detachment (PED) involving the fovea.
4. History of, or current clinical evidence in the study eye of aphakia, diabetic macularedema, any ocular inflammation or infection, pathological myopia, retinal detachment,advanced glaucoma, and/or significant media opacity, including cataract.
5. History or evidence of the following surgeries in the study eye: penetratingkeratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening.
6. Uncontrolled hypertension despite the use of antihypertensive medications.
7. Diagnosis of Type 1 or Type 2 diabetes.
8. Use of medications that in the opinion of the Investigator could interfere with studyresults.
9. Participation in any investigational drug or device study, systemic or ocular, withinthe past 3 months.
10. Women who are pregnant or breast feeding.
11. Women of child-bearing potential who are not using an effective form of birth control.
12. Known serious allergies or hypersensitivity to the fluorescein dye used inangiography, or to the components of the MG-O-1002 formulation, or to topicalanesthetics.
13. In the opinion of the investigator, subject who is not suitable for or not likely bebenefited from the study treatment. Part 2:
14. More than 30 days between 3rd injection of Aflibercept and Visit 1.
15. Patients who have received 3 injections of Aflibercept within the last 3 months andneed continued treatment in the fellow eye.
16. Significant retinal serous pigment epithelial detachment (PED), atrophy, orfibrosis/scar involving the fovea.
17. History or evidence of the following surgeries in the study eye: penetratingkeratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening.
18. Active intraocular inflammation or uveitis or scleritis or episcleritis in the studyeye or ocular or periocular infection in either eye.
19. Uncontrolled hypertension despite the use of antihypertensive medications.
20. Diagnosis of Type 1 or Type 2 diabetes.
21. Use of medications that in the opinion of the Investigator could interfere with studyresults.
22. Participation in any investigational drug or device study, systemic or ocular, withinthe past 3 months.
23. Women who are pregnant or breast feeding.
24. Women of child-bearing potential who are not using an effective form of birth control.
25. Known serious allergies or hypersensitivity to the fluorescein dye used inangiography, or to the components of the MG-O-1002 formulation, or to topicalanesthetics.
26. In the opinion of the investigator, subject who is not suitable for or not likely bebenefited from the study treatment.